JP6151515B2 - 神経膠芽腫ｇｂｍを治療するための組成物および方法 - Google Patents

神経膠芽腫ｇｂｍを治療するための組成物および方法 Download PDF

Info

Publication number
JP6151515B2
JP6151515B2 JP2012547587A JP2012547587A JP6151515B2 JP 6151515 B2 JP6151515 B2 JP 6151515B2 JP 2012547587 A JP2012547587 A JP 2012547587A JP 2012547587 A JP2012547587 A JP 2012547587A JP 6151515 B2 JP6151515 B2 JP 6151515B2
Authority
JP
Japan
Prior art keywords
seq
wild type
sequence shown
copy
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012547587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516456A (ja
JP2013516456A5 (enExample
Inventor
ヤエル コーエン
ヤエル コーエン
リブナット バンジオ
リブナット バンジオ
アンドリュー ジェイ． ブレンナー
アンドリュー ジェイ． ブレンナー
エヤル ブレイトバート
エヤル ブレイトバート
Original Assignee
バスキュラー バイオジェニックス リミテッド
バスキュラー バイオジェニックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バスキュラー バイオジェニックス リミテッド, バスキュラー バイオジェニックス リミテッド filed Critical バスキュラー バイオジェニックス リミテッド
Publication of JP2013516456A publication Critical patent/JP2013516456A/ja
Publication of JP2013516456A5 publication Critical patent/JP2013516456A5/ja
Application granted granted Critical
Publication of JP6151515B2 publication Critical patent/JP6151515B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2012547587A 2010-01-05 2011-01-05 神経膠芽腫ｇｂｍを治療するための組成物および方法 Expired - Fee Related JP6151515B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28222810P 2010-01-05 2010-01-05
US61/282,228 2010-01-05
US28224810P 2010-01-07 2010-01-07
US61/282,248 2010-01-07
PCT/IL2011/000009 WO2011083466A1 (en) 2010-01-05 2011-01-05 Compositions and methods for treating glioblastoma gbm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001588A Division JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫ｇｂｍを治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013516456A JP2013516456A (ja) 2013-05-13
JP2013516456A5 JP2013516456A5 (enExample) 2014-02-20
JP6151515B2 true JP6151515B2 (ja) 2017-06-21

Family

ID=44305240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012547587A Expired - Fee Related JP6151515B2 (ja) 2010-01-05 2011-01-05 神経膠芽腫ｇｂｍを治療するための組成物および方法
JP2016001588A Pending JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫ｇｂｍを治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016001588A Pending JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫ｇｂｍを治療するための組成物および方法

Country Status (10)

Country Link
US (2) US20130209450A1 (enExample)
EP (1) EP2521777B1 (enExample)
JP (2) JP6151515B2 (enExample)
KR (1) KR101810257B1 (enExample)
AU (1) AU2011204407B2 (enExample)
CA (1) CA2786377C (enExample)
MX (1) MX338931B (enExample)
NZ (1) NZ601325A (enExample)
SG (2) SG10201500048SA (enExample)
WO (1) WO2011083466A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN101570764A (zh) 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
AU2007280017B2 (en) 2006-07-31 2012-04-12 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
AU2009312355C1 (en) 2008-11-06 2016-02-18 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
SG10201500013SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ707336A (en) 2012-10-17 2019-01-25 Vascular Biogenics Ltd Treatment methods using adenovirus
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
WO2015048468A1 (en) 2013-09-27 2015-04-02 Mevion Medical Systems, Inc. Particle beam scanning
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
CN109803723B (zh) 2016-07-08 2021-05-14 迈胜医疗设备有限公司 一种粒子疗法系统
NZ752894A (en) 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
EP3645111B1 (en) 2017-06-30 2025-04-23 Mevion Medical Systems, Inc. Configurable collimator controlled using linear motors
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
US11291861B2 (en) 2019-03-08 2022-04-05 Mevion Medical Systems, Inc. Delivery of radiation by column and generating a treatment plan therefor
KR20210139329A (ko) * 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 항종양 요법의 방법
WO2020208612A1 (en) 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy
US20220370716A1 (en) * 2021-05-19 2022-11-24 Alcyone Therapeutics, Inc Fluid delivery systems and methods of treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
IL130608A0 (en) 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
ES2425321T3 (es) 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CN101570764A (zh) 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
US20080063656A1 (en) 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
WO2006079176A1 (en) 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
TWI421078B (zh) 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
AU2007280017B2 (en) 2006-07-31 2012-04-12 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
SG10201500013SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
SG10201500015TA (en) 2010-01-12 2015-02-27 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
NZ707336A (en) 2012-10-17 2019-01-25 Vascular Biogenics Ltd Treatment methods using adenovirus

Also Published As

Publication number Publication date
CA2786377C (en) 2018-02-27
US20130209450A1 (en) 2013-08-15
MX2012007850A (es) 2012-12-05
AU2011204407A1 (en) 2012-08-09
CA2786377A1 (en) 2011-07-14
JP2013516456A (ja) 2013-05-13
SG182366A1 (en) 2012-08-30
MX338931B (es) 2016-05-06
EP2521777A1 (en) 2012-11-14
EP2521777B1 (en) 2016-12-28
WO2011083466A1 (en) 2011-07-14
KR20120120942A (ko) 2012-11-02
US20130303595A1 (en) 2013-11-14
NZ601325A (en) 2014-09-26
AU2011204407B2 (en) 2015-05-07
JP2016128440A (ja) 2016-07-14
US10369196B2 (en) 2019-08-06
KR101810257B1 (ko) 2017-12-18
SG10201500048SA (en) 2015-03-30
EP2521777A4 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
JP6151515B2 (ja) 神経膠芽腫ｇｂｍを治療するための組成物および方法
KR101396454B1 (ko) 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여 혈관신생을 조절하는 방법
JP6196040B2 (ja) 特異的な抗血管形成アデノウイルス剤の使用法
AU2018271398B2 (en) Treatment methods using adenovirus
CN101443049A (zh) 表现出内皮细胞特异性的启动子和使用其调节血管生成的方法
CN103276015A (zh) 表现出内皮细胞特异性的启动子和使用其调节血管生成的方法
HK1175107A (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
HK1175107B (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
HK1143078B (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150323

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170525

R150 Certificate of patent or registration of utility model

Ref document number: 6151515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees